<!DOCTYPE html><html class="" lang="en"><head>
<!-- REQUIRED META INFORMATION -->
<meta charset="UTF-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta name="viewport" content="width=device-width, initial-scale=1">

<meta name="DCTERMS:contentOwner" content="TNeville">
<meta name="DCTERMS:contentOffice" content="DCRDP:ODP:OMP">

<meta name="DCTERMS:coder" content="^ORDP Webmaster">
<meta name="DCTERMS:coderOffice" content="DCRDP:ODEPPIN:OPPS">

<meta name="description" content="6.00-Genitourinary-Adult">
<meta name="DCTERMS:dateCertified" content="2019-11-25">
 
<!-- DOCUMENT TITLE -->
<title>6.00 Genitourinary Disorders - Adult | Disability | SSA</title>
 
<!-- STYLES -->
<link rel="stylesheet" href="/framework/css/ssa.firefly.css">

<!-- SCRIPTS -->
<script type="text/javascript" async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-TL5XBDT&amp;gtm=4e5b50"></script><script async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-5GQXH7Q"></script><script src="/framework/js/ssa.firefly.head.js"></script>


<script>(window.BOOMR_mq=window.BOOMR_mq||[]).push(["addVar",{"rua.upush":"false","rua.cpush":"false","rua.upre":"false","rua.cpre":"false","rua.uprl":"false","rua.cprl":"false","rua.cprf":"false","rua.trans":"","rua.cook":"false","rua.ims":"false","rua.ufprl":"false","rua.cfprl":"false","rua.isuxp":"false","rua.texp":"norulematch","rua.ceh":"false","rua.ueh":"false","rua.ieh.st":"0"}]);</script>
                              <script>!function(e){var n="https://s.go-mpulse.net/boomerang/";if("False"=="True")e.BOOMR_config=e.BOOMR_config||{},e.BOOMR_config.PageParams=e.BOOMR_config.PageParams||{},e.BOOMR_config.PageParams.pci=!0,n="https://s2.go-mpulse.net/boomerang/";if(window.BOOMR_API_key="LERZW-HECFS-R8H4E-23UQ7-ERMQB",function(){function e(){if(!o){var e=document.createElement("script");e.id="boomr-scr-as",e.src=window.BOOMR.url,e.async=!0,i.parentNode.appendChild(e),o=!0}}function t(e){o=!0;var n,t,a,r,d=document,O=window;if(window.BOOMR.snippetMethod=e?"if":"i",t=function(e,n){var t=d.createElement("script");t.id=n||"boomr-if-as",t.src=window.BOOMR.url,BOOMR_lstart=(new Date).getTime(),e=e||d.body,e.appendChild(t)},!window.addEventListener&&window.attachEvent&&navigator.userAgent.match(/MSIE [67]\./))return window.BOOMR.snippetMethod="s",void t(i.parentNode,"boomr-async");a=document.createElement("IFRAME"),a.src="about:blank",a.title="",a.role="presentation",a.loading="eager",r=(a.frameElement||a).style,r.width=0,r.height=0,r.border=0,r.display="none",i.parentNode.appendChild(a);try{O=a.contentWindow,d=O.document.open()}catch(_){n=document.domain,a.src="javascript:var d=document.open();d.domain='"+n+"';void(0);",O=a.contentWindow,d=O.document.open()}if(n)d._boomrl=function(){this.domain=n,t()},d.write("<bo"+"dy onload='document._boomrl();'>");else if(O._boomrl=function(){t()},O.addEventListener)O.addEventListener("load",O._boomrl,!1);else if(O.attachEvent)O.attachEvent("onload",O._boomrl);d.close()}function a(e){window.BOOMR_onload=e&&e.timeStamp||(new Date).getTime()}if(!window.BOOMR||!window.BOOMR.version&&!window.BOOMR.snippetExecuted){window.BOOMR=window.BOOMR||{},window.BOOMR.snippetStart=(new Date).getTime(),window.BOOMR.snippetExecuted=!0,window.BOOMR.snippetVersion=12,window.BOOMR.url=n+"LERZW-HECFS-R8H4E-23UQ7-ERMQB";var i=document.currentScript||document.getElementsByTagName("script")[0],o=!1,r=document.createElement("link");if(r.relList&&"function"==typeof r.relList.supports&&r.relList.supports("preload")&&"as"in r)window.BOOMR.snippetMethod="p",r.href=window.BOOMR.url,r.rel="preload",r.as="script",r.addEventListener("load",e),r.addEventListener("error",function(){t(!0)}),setTimeout(function(){if(!o)t(!0)},3e3),BOOMR_lstart=(new Date).getTime(),i.parentNode.appendChild(r);else t(!1);if(window.addEventListener)window.addEventListener("load",a,!1);else if(window.attachEvent)window.attachEvent("onload",a)}}(),"".length>0)if(e&&"performance"in e&&e.performance&&"function"==typeof e.performance.setResourceTimingBufferSize)e.performance.setResourceTimingBufferSize();!function(){if(BOOMR=e.BOOMR||{},BOOMR.plugins=BOOMR.plugins||{},!BOOMR.plugins.AK){var n=""=="true"?1:0,t="cookiepresent",a="im6jsaqxzhbro2ioayxa-f-f85ccea90-clientnsv4-s.akamaihd.net",i="false"=="true"?2:1,o={"ak.v":"39","ak.cp":"1204614","ak.ai":parseInt("728289",10),"ak.ol":"0","ak.cr":20,"ak.ipv":4,"ak.proto":"h3","ak.rid":"ca1632e","ak.r":39734,"ak.a2":n,"ak.m":"dsca","ak.n":"essl","ak.bpcip":"67.60.153.0","ak.cport":57631,"ak.gh":"23.201.194.23","ak.quicv":"0x00000001","ak.tlsv":"tls1.3","ak.0rtt":"","ak.0rtt.ed":"","ak.csrc":"-","ak.acc":"","ak.t":"1762526766","ak.ak":"hOBiQwZUYzCg5VSAfCLimQ==DBmkDRIwBOG5O1oirOQJIG6tL77PUQNsUmqJQcxCBvFOygebFE4awd6BNVU2j+9DGZy7k/tbIUvHf2s/Uwsm5xEV7x3uUXq9Jkt0KivjWlj/1blYijCSl+6CdL5BjwQPYRd/Xpx8VHgQSEHON1+13mY82LDjmWaiRplTU3OwKvlgL+hPaYKFXT72YB7NUZamTxg6YU+x37N6U2dOjqsQwOUdPDKNps6bihWRwN0dm04HbN2nDPM6riHnVeafZTXwEd9zXyq/c9/m6cJpe/aR/xEXEy5GlU08v/bxPFkvlgT64ffoUCTVn2kZ+ujT1YlLyczZ/13/IMH1o2/C7cnEaY7DLt+4tabkeyDcA/ukfv87wKwHTASWY4EUdrOpnZAiSNVzCsYD6GB1QRDuHkv0MaNpNFQKXkMcQm4du/OjePw=","ak.pv":"120","ak.dpoabenc":"","ak.tf":i};if(""!==t)o["ak.ruds"]=t;var r={i:!1,av:function(n){var t="http.initiator";if(n&&(!n[t]||"spa_hard"===n[t]))o["ak.feo"]=void 0!==e.aFeoApplied?1:0,BOOMR.addVar(o)},rv:function(){var e=["ak.bpcip","ak.cport","ak.cr","ak.csrc","ak.gh","ak.ipv","ak.m","ak.n","ak.ol","ak.proto","ak.quicv","ak.tlsv","ak.0rtt","ak.0rtt.ed","ak.r","ak.acc","ak.t","ak.tf"];BOOMR.removeVar(e)}};BOOMR.plugins.AK={akVars:o,akDNSPreFetchDomain:a,init:function(){if(!r.i){var e=BOOMR.subscribe;e("before_beacon",r.av,null,null),e("onbeacon",r.rv,null,null),r.i=!0}return this},is_complete:function(){return!0}}}}()}(window);</script><link href="https://s.go-mpulse.net/boomerang/LERZW-HECFS-R8H4E-23UQ7-ERMQB" rel="preload" as="script"><style>@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.ttf) format("truetype");font-weight:300;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.ttf) format("truetype");font-weight:400;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.ttf) format("truetype");font-weight:600;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.ttf) format("truetype");font-weight:700;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.ttf) format("truetype");font-weight:800;font-style:normal;font-display:swap}</style><meta property="og:site_name" content="Social Security"><meta property="og:type" content="website"><meta property="og:url" content="https://www.ssa.gov/disability/professionals/bluebook/6.00-Genitourinary-Adult.htm"><meta property="og:title" content="6.00 Genitourinary Disorders - Adult | Disability | SSA"><meta property="og:description" content="6.00-Genitourinary-Adult"><meta property="og:image:url" content="https://www.ssa.gov/themes/custom/ssa_core/logo.svg"><meta property="og:image:secure_url" content="https://www.ssa.gov/themes/custom/ssa_core/logo.svg"><meta property="og:image:alt" content="U.S. Social Security Administration"><meta property="og:locale" content="en_US"><meta property="og:locale:alternate" content="es_ES"><script id="boomr-scr-as" src="https://s.go-mpulse.net/boomerang/LERZW-HECFS-R8H4E-23UQ7-ERMQB" async=""></script></head>

<body style="margin: 0px;">
  <!-- BANNER -->
  <aside class="accessibility" id="accessibility"><a href="#content" id="skip-navigation">Skip to main content</a></aside>
<!-- WCMS SITE ALERT (EMERGENCY) -->
<div class="wsa" aria-label="Site Alert" data-type="emergency">
  <div class="wsag">
    <svg focusable="false" height="26" width="26" viewBox="0 0 20 20" aria-hidden="true">
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,15h-1.7v-1.7h1.7v1.7ZM10.8,11.7h-1.7v-4.9h1.7v4.9Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#1C1D1F" fill-rule="evenodd" stroke-width="0" d="M.8,17.5h18.3L10,1.7.8,17.5ZM10.8,15h-1.7v-1.7h1.7v1.7ZM10.8,11.7h-1.7v-4.9h1.7v4.9h0Z" vector-effect="non-scaling-stroke"></path>
    </svg>
    <div>
      <a href="/myaccount/"><u>Social Security and SSI Payments will Continue during the Government Shutdown.  Visit my Social Security for Online Services.</u></a>
    </div>
  </div>
</div>
<!-- WCMS SITE ALERT (INFORMATION) -->
<div class="wsa" aria-label="Site Alert" data-type="information">
  <div class="wsag">
    <svg focusable="false" height="26" width="26" viewBox="0 0 20 20" aria-hidden="true">
      <path fill="#1C1D1F" fill-rule="evenodd" stroke-width="0" d="M10,1.7C5.4,1.7,1.7,5.4,1.7,10s3.7,8.3,8.3,8.3,8.3-3.7,8.3-8.3S14.6,1.7,10,1.7ZM9.2,7.5v-1.7h1.7v1.7h-1.7ZM9.2,9.2v5h1.7v-5h-1.7Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,7.5h-1.7v-1.7h1.7v1.7Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,14.2h-1.7v-5h1.7v5Z" vector-effect="non-scaling-stroke"></path>
    </svg>
    <div>
      <a href="https://www.ssa.gov/manage-benefits/get-benefit-letter"><u>Get a benefit verification letter.</u></a>
    </div>
  </div>
</div>
<ssa-header class="print-dn"></ssa-header><script src="https://www.ssa.gov/legacy/components/dist/ssa-header.js"></script>
  <!-- MAIN CONTENT -->
  <main class="content" id="content" role="main">
    <!-- TITLE BAR -->
    <section class="bg-ivory-200">
      <!-- WRAPPER -->
      <div class="py2 wrapper">
        <h2 class="fw4 ma0" id="Top">Medical/Professional Relations</h2>
        </div>
    </section>

    <!-- WRAPPER -->
    <section class="wrapper">
    
    <!--GRID-->
<div class="grid">
	
<!-- FIRST COLUMN -->
<article class="cell w-100 m-w-100">
	
<!-- BREADCRUMBS -->
<nav class="breadcrumbs fs1" aria-label="Breadcrumbs">
  <ol>
    <li><a href="https://www.ssa.gov">SSA Home</a></li>
	<li><a href="https://www.ssa.gov/disability">Disability</a></li>
	<li><a href="../index.htm">Medical/Professional Relations</a></li>
	<li><a href="index.htm">Disability Evaluation Under Social Security</a></li>
	<li><a href="AdultListings.htm">Listing of Impairments - Adult Listings (Part A)</a></li> 
    <li aria-current="page">6.00 Genitourinary Disorders - Adult </li>
  </ol>
</nav>
</article><!--END FIRST COLUMN-->

<!-- FIRST COLUMN -->
<article class="cell w-100 m-w-20">


<p class="js-toggle"><a href="AdultListings.htm">Adult Listings (Part A)</a></p>
<p class="js-toggle"><a href="ChildhoodListings.htm">Childhood Listings (Part B)</a></p>
<p class="js-toggle"><a href="general-info.htm">General Information</a></p>
<p class="js-toggle"><a href="evidentiary.htm">Evidentiary Requirements</a></p>
<p class="js-toggle"><a href="listing-impairments.htm">Listing of Impairments (overview) </a></p>

<p class="js-toggle"><a href="revisions-rules.html">Revisions to Rules Regarding the Evaluation of Medical Evidence</a></p>
                          </article><!-- END FIRST COLUMN-->

<!--SECOND COLUMN-->
<article class="cell w-100 m-w-80">

   <h2><span><b> Disability Evaluation Under Social Security<br>
        <br>
        <strong>
        6.00 Genitourinary Disorders</strong> - Adult<br>
        &nbsp;</b></span></h2>


                            <!--GRID-->
					<div class="grid">

                         <!--FIRST INNER COLUMN-->
					<article class="cell w-100 m-w-20">

<u><b>Section</b></u><br><br>
      <p align="left"> 
    <a href="#6_01" title=" 6.01 Category of Impairments, Genito-Urinary System"><b>6.01</b><br>Category of<br>Impairments,<br>Genitourinary Disorders</a>				
			<br><br>
              <a href="#6_03" title=" 6.03 Chronic kidney disease"> <b>6.03</b><br>Chronic kidney <br>
              disease, with <br>
              chronic hemodialysis <br>
              or peritoneal dialysis</a></p>
      <p align="left"><a href="#6_04" title=" 6.04 Chronic kidney disease"><b>6.04</b><br>
        Chronic kidney <br>
disease, with <br>
kidney transplant </a></p>
      <p align="left"><a href="#6_05" title=" 6.05 Chronic kidney disease"><b>6.05</b><br>
Chronic kidney <br>
disease, with <br>
impairment of <br>
kidney function</a><br>
        <br>
        <a href="#6_06" title=" 6.06 Nephrotic syndrome, with significant anasarca, persistent for at least 3 months despite prescribed therapy"><b>6.06</b><br>
        Nephrotic syndrome</a></p>
      <p align="left"><a href="#6_09" title="6.09 Complications of chronic kidney disease"><strong>6.09</strong> <br>
        Complications of <br>
        chronic kidney disease</a></p>
        
                            </article><!--END FIRST INNER COLUMN-->

							<!--SECOND inner COLUMN-->
							<article class="cell w-100 m-w-80">
                            
      <p id="6_00"><u><b>6.00 Genitourinary Disorders</b></u><br></p>
      <p id="6_00A">A.<em> Which disorders do we evaluate under these  listings?</em>   </p>
      <p>We evaluate genitourinary disorders resulting in chronic  kidney disease (CKD). Examples of such disorders include chronic  glomerulonephritis, hypertensive nephropathy, diabetic nephropathy, chronic  obstructive uropathy, and hereditary nephropathies. We also evaluate nephrotic  syndrome due to glomerular dysfunction under these listings.</p>
      <div align="left">
          <p id="6_00B">B. <em>What evidence do we need?</em> </p>
          <ol>
              <li id="6_00B1">
                  We need evidence that documents the signs, symptoms, and laboratory findings of your CKD. This  evidence should include reports of clinical examinations, treatment records,  and documentation of your response to treatment. Laboratory findings, such as  serum creatinine or serum albumin levels, may document your kidney function. We  generally need evidence covering a period of at least 90 days unless we can  make a fully favorable determination or decision without it.<br>
                  <br>
              </li>
              <li id="6_00B2">
                  <em>Estimated glomerular filtration rate (eGFR)</em>.
                  The eGFR is an estimate of the filtering capacity of the kidneys that takes into account serum creatinine concentration and other variables, such as your age, gender, and body size.
                  If your medical evidence includes eGFR findings, we will consider them when we evaluate your CKD under <a href="#6_05" title="Section 6.05">6.05</a><br>
                  <br>
              </li>
              <li id="6_00B3">
                  <em>Kidney or bone biopsy</em>. If you have had a kidney or bone biopsy, we  need a copy of the pathology report. When we cannot get a copy of the pathology  report, we will accept a statement from an acceptable medical source verifying  that a biopsy was performed and describing the results.
                  <br>
              </li>
          </ol>
          <p id="6_00C"><em>C. What other factors do we consider when we evaluate your genitourinary disorder?</em></p>
          <ol type="1">
              <li id="6_00C1">
                  <em>Chronic hemodialysis or peritoneal dialysis</em>.<br>
                  <br>
                  <ol type="a">
                      <li id="6_00C1a">
                          Dialysis is a treatment for CKD that uses artificial means to remove toxic metabolic byproducts from the blood.
                          Hemodialysis uses an artificial kidney machine to clean waste products from the blood;
                          peritoneal dialysis uses a dialyzing solution that is introduced into and removed from the abdomen (peritoneal cavity) either continuously or intermittently.
                          Under <a href="#6_03" title="Section 6.03">6.03</a>, your ongoing dialysis must have lasted or be expected to last for a continuous period of at least 12 months.
                          To satisfy the requirements in <a href="#6_03" title="Section 6.03">6.03</a>, we will accept a report from an acceptable medical source that describes your CKD and your current dialysis,
                          and indicates that your dialysis will be ongoing.<br>
                          <br>
                      </li>
                      <li id="6_00C1b">
                          If you are undergoing chronic hemodialysis or peritoneal dialysis, your CKD may meet our definition  of disability before you started dialysis. We will determine the onset of your  disability based on the facts in your case record.<br>
                          <br>
                      </li>
                  </ol>
              </li><li id="6_00C2">
                  <em>Kidney transplant.</em><br>
                  <br>
              </li>

              <ol type="a">
                  <li id="6_00C2a">
                      If you receive a kidney transplant, we will consider you to be disabled under <a href="#6_04" title="Section 6.04">6.04</a> for 1 year from the date of transplant.
                      After that, we will evaluate your residual  impairment(s) by considering your post-transplant function, any rejection  episodes you have had, complications in other body systems,
                      and any adverse effects related to ongoing treatment.<br>
                      <br>
                  </li>
                  <li id="6_00C2b">
                      If you received a kidney transplant, your CKD may meet our definition of disability before you  received the transplant. We will determine the onset of your disability based  on the facts in your case record.<br>
                      <br>
                  </li>
              </ol>
              <li id="6_00C3">
                  <em>Renal osteodystrophy</em>. This condition is the bone degeneration resulting from chronic kidney disease-mineral and bone disorder (CKD-MBD).
                  CKD-MBD occurs when the kidneys are unable to maintain the necessary levels of  minerals, hormones, and vitamins required for bone structure and function.
                  Under <a href="#6_05B1" title="Section 6.05 - Subsection B1">6.05B1</a>, “severe bone pain” means frequent or intractable (resistant to  treatment)
                  bone pain that interferes with physical activity or mental functioning.<br>
                  <br>
              </li>
              <li id="6_00C4">
                  <em>Peripheral neuropathy</em>. This disorder results when the kidneys do not adequately filter toxic substances from the blood. These toxins can adversely affect nerve tissue.
                  The resulting neuropathy may affect peripheral motor or  sensory nerves, or both, causing pain, numbness, tingling, and muscle weakness in various parts of the body.
                  Under <a href="#6_05B2" title="Section 6.05 - Subsection B2">6.05B2</a>, the peripheral neuropathy must be a severe impairment.
                  (See §§ <a href="https://www.ssa.gov/OP_Home/cfr20/404/404-1520.htm#c" target="_blank" title="Code of Federal Regulations section 404.1520 - Subsection c">404.1520(c)</a>,
                  <a href="https://www.ssa.gov/OP_Home/cfr20/404/404-1521.htm" target="_blank" title="Code of Federal Regulations section 404.1521">404.1521</a>,
                  <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0920.htm#c" target="_blank" title="Code of Federal Regulations section 416.920 - Subsection c">416.920(c)</a>,
                  and <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0921.htm" target="_blank" title="Code of Federal Regulations section 416.921">416.921</a> of this chapter.)
                  It must also have lasted or be expected to last for a continuous period of at least 12 months.<br>
                  <br>
              </li>
              <li id="6_00C5">
                  <em>Fluidoverload syndrome</em>. This condition occurs when excess sodium and water retention in the body due to CKD results in vascular congestion.
                  Under <a href="#6_05B3" title="Section 6.05 - Subsection B3">6.05B3</a>, we need a description of a physical examination that documents signs and symptoms of vascular congestion, such as congestive heart failure,
                  pleural effusion (excess fluid in the chest), ascites (excess fluid in the abdomen), hypertension, fatigue, shortness of breath, or peripheral edema.                   <br>
                  <br>
              </li>
              <li id="6_00C6">
                  <em>Anasarca</em> (generalized massive edema or swelling).
                  Under <a href="#6_05B3" title="Section 6.05 - Subsection B3">6.05B3</a> and <a href="#6_06B" title="Section 6.06 - Subsection B">6.06B</a>, we need a description of the extent of edema,
                  including pretibial (in front of the tibia), periorbital (around the eyes), or presacral (in front of the sacrum) edema. We also need a description of any ascites, pleural effusion, or pericardial effusion.<br>
                  <br>
              </li>
              <li id="6_00C7">
                  <em>Anorexia (diminished appetite) with weight loss</em>. Anorexia is a frequent sign of CKD and can result in weight loss.
                  We will use body mass index (BMI) to determine the  severity of your weight loss under <a href="#6_05B4" title="Section 6.05 - Subsection B4">6.05B4</a>.
                  (BMI is the ratio of your measured  weight to the square of your measured height.)
                  We calculate your BMI using the formulas in the digestive disorders body system (<a href="5.00-Digestive-Adult.htm#5_00" title="5.00 Digestive System Page, Section 5.00" target="_blank">5.00</a>).
                  <br>
                  <br>
              </li>
              <li id="6_00C8">
                  <em>Complications of CKD</em>.
                  The hospitalizations in <a href="#6_09" title="Section 6.09">6.09</a> may be for  different complications of CKD.
                  Examples of complications from CKD that may  result in hospitalization include stroke, congestive heart failure,  hypertensive crisis, or acute kidney failure requiring a short course of  hemodialysis.
                  If the CKD complication occurs during a hospitalization that was  initially for a co-occurring condition, we will evaluate it under our rules for  determining medical equivalence.
                  (See §§<a href="https://www.ssa.gov/OP_Home/cfr20/404/404-1526.htm" target="_blank" title="Code of Federal Regulations section 404.1526">404.1526</a>
                  and <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0926.htm" target="_blank" title="Code of Federal Regulations section 416.926">416.926</a> of this chapter.)  We will evaluate co-occurring conditions,
                  including those that result in hospitalizations, under the  listings for the affected body system or under our rules for medical  equivalence.
              </li>
			
          </ol>
          <p id="6_00D">
              D.
              <em>How do we evaluate disorders that do not meet one of the genitourinary listings?</em>
          </p>
          <ol>
              <li id="6_00D1">
                  The listed disorders are only examples of common genitourinary disorders that we consider severe enough to prevent you from doing any gainful activity. If your impairment(s) does not meet the criteria of any of these listings, we must also consider  whether you have an impairment(s) that satisfies the criteria of a listing in  another body system.<br>
                  <br>
              </li>
              <li id="6_00D2">
                  If you have a severe medically determinable impairment(s) that does not meet a listing, we will determine whether your impairment(s) medically equals a listing.
                  (See  §§<a href="https://www.ssa.gov/OP_Home/cfr20/404/404-1526.htm" target="_blank" title="Code of Federal Regulations section 404.1526">404.1526</a>
                  and <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0926.htm" target="_blank" title="Code of Federal Regulations section 416.926">416.926</a> of this chapter.)
                  Genitourinary disorders may be associated with disorders in other body systems, and we consider the combined effects of multiple impairments when we determine whether they medically equal a listing.
                  If your impairment(s) does not meet or medically equal the criteria  of a listing, you may or may not have the residual functional capacity to  engage in substantial gainful activity.
                  We proceed to the fourth and, if necessary,
                  the fifth steps of the sequential evaluation process in §§<a href="https://www.ssa.gov/OP_Home/cfr20/404/404-1520.htm" target="_blank" title="Code of Federal Regulations section 404.1520">404.1520</a>
                  and <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0920.htm" target="_blank" title="Code of Federal Regulations section 416.920">416.920</a> of this chapter.
                  We use the rules in §§<a href="https://www.ssa.gov/OP_Home/cfr20/404/404-1594.htm" target="_blank" title="Code of Federal Regulations section 404.1594">404.1594</a>
                  and <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0994.htm" target="_blank" title="Code of Federal Regulations section 416.994">416.994</a> of this  chapter, as appropriate, when we decide whether you continue to be disabled.<br>&nbsp;
              </li>
          </ol>
      </div>
      <p align="left"><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b> </p>
      <p align="left" id="6_01">
          <b>
              
                  6.01 Category of Impairments, Genitourinary
                  Disorders
          </b>
      </p>
      <p align="left"><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
      <!--<p align="left"><b><a name="6_03" id="6_03"> 6.03 <em>Chronic kidney disease,</em> </a></b>with chronic hemodialysis or peritoneal  dialysis (see <a href="#6_00C1" title="Section 6.00 - Subsection C1">6.00C1</a>).</a></p>-->
      <p align="left" id="6_03"><b>6.03 <em>Chronic kidney disease,</em></b>with chronic hemodialysis or peritoneal  dialysis (see <a href="#6_00C1" title="Section 6.00 - Subsection C1">6.00C1</a>).</p>
      <p align="left"><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
      <p id="6_04"><strong>6.04 <em>Chronic kidney  disease,</em></strong> 
      with kidney transplant. Consider under a disability for 1 year  following the transplant; thereafter, evaluate the residual impairment (see <a href="#6_00C2" title="Section 6.00 - Subsection C2">6.00C2</a>).</p>
      <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
      <p id="6_05"><strong>6.05 <em>Chronic kidney disease</em>,</strong> with impairment  of kidney function, with A and B:</p>
      <p id="6_05A">A. Reduced glomerular filtration evidenced by one of the  following laboratory findings documented on at least two occasions at least 90  days apart during a consecutive 12-month period:</p>
      <ol>
          <li id="6_05A1">
              Serum  creatinine of 4 mg/dL or greater; or<br>
              <br>
          </li>
          <li id="6_05A2">
              Creatinine clearance of 20 ml/min. or less; or <br>
              <br>
          </li>
          <li id="6_05A3">Estimated glomerular filtration rate (eGFR) of 20 ml/min/1.73m2 or  less.</li>
      </ol>
      <p>AND</p>
      <p id="6_05B">B. One of the following:</p>
      <ol>
          <li id="6_05B1">
              Renal  osteodystrophy (see <a href="#6_00C3" title="Section 6.00 - Subsection C3">6.00C3</a>) with severe bone pain and imaging studies  documenting bone abnormalities, such as osteitis fibrosa, osteomalacia, or  pathologic fractures; or<br>
    <br>
</li>
          <li id="6_05B2">
              Peripheral neuropathy (see <a href="#6_00C4" title="Section 6.00 - Subsection C4">6.00C4</a>); or<br>
    <br>
</li>
          <li id="6_05B3">
              Fluid  overload syndrome (see <a href="#6_00C5" title="Section 6.00 - Subsection C5">6.00C5</a>) documented by one of the following:<br>
    <br>
</li>
          <ol type="a">
              <li id="6_05B3a">
                  Diastolic hypertension greater than or equal to diastolic blood pressure of 110 mm Hg despite at least 90 consecutive days of prescribed therapy, documented by at least two measurements of diastolic blood pressure at least 90 days apart  during a consecutive 12-month period; or<br>
                  <br>
              </li>
              <li id="6_05B3b">
                  Signs of vascular congestion or anasarca (see <a href="#6_00C6" title="Section 6.00 - Subsection C6">6.00C6</a>) despite at least 90 consecutive days of prescribed therapy, documented on at least two occasions at least 90  days apart during a consecutive 12-month period; or<br>
    <br>
</li>
          </ol>
          <li id="6_05B4">
             Anorexia with weight loss (see <a href="#6_00C7" title="Section 6.00 - Subsection C7">6.00C7</a>) determined by body mass index (BMI) of 18.0 or less,
    calculated on at least two occasions at least 90 days apart during a consecutive 12-month period.<br>
</li>

      </ol>
      <p align="left"><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
      <p align="left" id="6_06"><b><em>6.06  Nephrotic syndrome, </em></b>with A and B</p>
      <p id="6_06A">A. Laboratory findings as described in 1 or 2, documented on at  least two occasions at least 90 days apart during a consecutive 12-month  period:</p>
      <ol>
          <li id="6_06A1">
              Proteinuria of 10.0 g or greater per 24 hours; or<br>
              <br>
          </li>
          <li id="6_06A2">
              Serum  albumin of 3.0 g/dL or less, and <br>
              <br>
          </li>
          <ol type="a">
              <li id="6_06A2a"> 
                  Proteinuria of 3.5 g or greater per 24 hours; or <br>
                  <br>
              </li>
              <li id="6_06A2b">Urine total-protein-to-creatinine ratio of 3.5 or greater.</li>
          </ol>
      </ol>
      <p>AND</p>
      <p id="6_06B">B. Anasarca (see <a href="#6_00C6" title="Section 6.00 - Subsection C6">6.00C6</a>) persisting for at least 90 days despite prescribed treatment.</p>
      <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
      <p id="6_09"><strong>6.09 <em>Complications of chronic kidney disease</em> </strong>
      (see <a href="#6_00C8" title="Section 6.00 - Subsection C8">6.00C8</a>) requiring at least three hospitalizations within a consecutive 12-month  period and occurring at least 30 days apart. 
      Each hospitalization must last at least 48 hours, including hours in a hospital emergency department immediately  before the hospitalization.</p>
      <p>
          <b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b>
      </p>
      
 </article><!-- END SECOND INNER COLUMN -->
 
 </div><!-- END GRID-->

</article><!-- END SECOND COLUMN -->

</div><!-- END GRID-->

    </section>
  </main>
  <!-- FOOTER -->
  <ssa-footer class="print-dn"></ssa-footer><script src="https://www.ssa.gov/legacy/components/dist/ssa-footer.js"></script>
  <!-- SCRIPTS -->
  <script src="/framework/js/ssa.firefly.body.js"></script><a class="js-btt" href="#" title="Back to Top"></a>


</body></html>